As of May 24, 2025, Haemonetics Corp (HAE) reports a Net Margin of 8.98%.
Net Margin shows the share of revenue that becomes profit after all costs, reflecting overall profitability.
Historical Trend of Haemonetics Corp's Net Margin
Over recent years, Haemonetics Corp's Net Margin has shown significant volatility. The table below summarizes the historical values:
| Date | Net Margin |
|---|---|
| 2024-03-30 | 8.98% |
| 2023-04-01 | 9.87% |
| 2022-04-02 | 4.37% |
| 2021-04-03 | 9.13% |
| 2020-03-28 | 7.74% |
This slight upward trend highlights how Haemonetics Corp manages its overall profitability and cost control over time.
Comparing Haemonetics Corp's Net Margin to Peers
To better understand Haemonetics Corp's position, it's useful to compare its Net Margin against industry peers. Below are selected comparisons:
| Company | Net Margin |
|---|---|
| Haemonetics Corp (HAE) | 8.98% |
| Utah Medical Products Inc (UTMD) | 33.92% |
| Antares Pharma Inc (ATRS) | 25.16% |
| Lantheus Holdings Inc (LNTH) | 20.37% |
| Meridian Bioscience Inc (VIVO) | 12.75% |
| Atrion Corp (ATRI) | 11.46% |
Compared to its competitors, Haemonetics Corp's Net Margin is among the highest compared to peers, suggesting strong overall cost management and pricing power.